| Off-label use of rituximab in systemic lupus erythematosus: a systematic review. | |
| | |
MedLine Citation:
|
PMID: 20155295 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two significant RCTs have reported negative findings, reopening the debate on clinical benefit. This review of the available data suggests that rituximab induces B-cell depletion in 95% of patients, and a significant reduction in disease activity is achieved with a relatively good safety profile in patients with SLE. |
| | |
Authors:
|
Eleanor Murray; Martin Perry |
Related Documents
:
|
3565435 - Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy. 17314445 - Mini outbreak of kaposi's varicelliform eruption in skin ward: a study of five cases. 3688755 - Pediatric laryngeal sarcoidosis. 7389185 - Xeroderma pigmentosum exhibiting neurological disorders and systemic lupus erythematosus. 21435415 - Caffeine and cardiac arrhythmias: a review of the evidence. 3316345 - Prolonged evaluation of patients with corticosteroid-dependent asthma stage of allergic... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-02-13 |
Journal Detail:
|
Title: Clinical rheumatology Volume: 29 ISSN: 1434-9949 ISO Abbreviation: Clin. Rheumatol. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-05-31 Completed Date: 2010-10-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8211469 Medline TA: Clin Rheumatol Country: Germany |
Other Details:
|
Languages: eng Pagination: 707-16 Citation Subset: IM |
Affiliation:
|
Western Infirmary General, G-3/4, Glasgow, G11 6NT, UK. eleanormurray@doctors.org.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects,
pharmacology,
therapeutic use* B-Lymphocytes / cytology, drug effects, immunology Down-Regulation / drug effects Humans Lupus Erythematosus, Systemic / drug therapy* Off-Label Use* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Artificial organs: recent progress in metals and ceramics.
Next Document: Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aur...